{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-21-000127","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2021-11-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.032063+00:00","generated_at":"2026-06-28T05:49:00.223263+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunovant enters $36M manufacturing deal with Samsung Biologics for batoclimab","bullets":["Minimum purchase commitment estimated at $36M; PSA runs through Dec 31, 2029.","Immunovant can terminate if it stops all batoclimab development by Jan 2024, paying non-cancellable fees.","Samsung will manufacture batoclimab drug substance for commercial sale, including process performance qualification batches.","Agreement builds on Master Services Agreement dated April 30, 2021.","Either party may terminate for material breach, insolvency, or force majeure."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-21-000127","json":"https://secwatch.observer/filing/0001764013-21-000127.json","markdown":"https://secwatch.observer/filing/0001764013-21-000127.md","text":"https://secwatch.observer/filing/0001764013-21-000127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000127/0001764013-21-000127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000127/imvt-20211117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T05:49:00.223263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}